Martin Hutchings from Copenhagen University Hospital discusses the ECHELON-1 trial and treatment strategies in Hodgkin’s lymphoma.
1. What are the limitations of current ABVD chemotherapy regimes for advanced Hodgkin’s lymphoma? (0:10)
2. Could you tell us a little about the ECHELON-1 study and its findings? (1:04)
3. What toxicities were associated with the A+AVD regimen? (2:11)
4. What patients are most likely to respond to this approach? (4:46)
5. What future studies are planned? (6:05)
Speaker disclosures: Martin Hutchings has nothing to disclose in relation to this video interview.
Filmed at the 23rd Annual Congress of the European Association of Hematology (EHA), Stockholm, Sweden, June 14–17 2018
A+AVD = brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine; ABVD = doxorubicin, bleomycin, vinblastine, and dacarbazine
Share this Video
Related Videos In Lymphoma
Theodoros P Vassilakopoulos, MD, PhD, EHA 2019 – Exciting new developments in Hodgkin lymphoma
At the EHA conference in Amsterdam we are joined by Professor Theodoros P Vassilakopoulos to discuss the most exciting new developments in standards of care for Hodgkin lymphoma. Questions 1. What are the limitations of current standards of care for Hodgkin lymphoma (HL)? (0:05) 2. What is the role of brentuximab vedotin in the current […]
Andrea Gallamini, EHA 2019 – Three-year Update of the ECHELON-1 Study
We are joined by Andrea Gallamini, at EHA 2019 to discuss his presentation on frontline brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Questions 1. Could you tell us a little about the ECHELON-1 study and its findings? (0:05) 2. What have we learned from the 3-year […]
Eva Domingo Domènech, EHA 2019 – The Phase II CHECKMATE 205 Study
We are joined by Eva Domingo Domènech at EHA 2019 to discuss her presentation on nivolumab plus doxorubicin, vinblastine and dacarbazine for newly diagnosed advanced-stage classical Hodgkin lymphoma: 2-year extended follow-up from cohort D of the phase II CHECKMATE 205 study. Questions 1. What are the major unmet needs in the treatment of advanced stage […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!